Analysts Issue Forecasts for Masimo FY2024 Earnings

Masimo Co. (NASDAQ:MASI) – Stock analysts at Zacks Research issued their FY2024 earnings per share estimates for shares of Masimo in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst I. Bandyopadhyay forecasts that the medical equipment provider will post earnings per share of $4.10 for the year. The consensus estimate for Masimo’s current full-year earnings is $4.10 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.49 EPS.

Several other equities research analysts have also recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Wells Fargo & Company boosted their target price on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Stock Performance

Shares of MASI opened at $169.96 on Monday. The stock has a 50-day simple moving average of $172.78 and a 200-day simple moving average of $152.24. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market capitalization of $9.10 billion, a PE ratio of 117.21 and a beta of 1.02. Masimo has a 1 year low of $101.61 and a 1 year high of $184.51.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MASI. Jones Financial Companies Lllp acquired a new position in Masimo during the fourth quarter worth approximately $27,000. UMB Bank n.a. increased its holdings in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont acquired a new position in shares of Masimo in the fourth quarter valued at approximately $33,000. Blue Trust Inc. increased its holdings in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.